Related Experiment Video

Updated: Jun 12, 2026

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

Gatekeeper mutations mediate resistance to BRAF-targeted therapies

Steven Whittaker1, Ruth Kirk, Robert Hayward

  • 1Institute of Cancer Research, London, UK.

Science Translational Medicine
|June 12, 2010
PubMed

Insights

Sorafenib inhibits cancer growth independently of BRAF, while PLX4720 directly targets BRAF. This study distinguishes drug mechanisms for oncogenic BRAF mutations.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • BRAF mutations drive 2% of human cancers by activating MEK-ERK signaling.
  • Targeting oncogenic BRAF is crucial for cancer therapy, but distinguishing direct effects from off-target actions is challenging.
  • Developing drugs that specifically inhibit BRAF is essential for effective cancer treatment.

Purpose of the Study:

  • To differentiate the antitumor mechanisms of BRAF inhibitors, specifically sorafenib and PLX4720.
  • To provide unequivocal evidence for how these drugs mediate their effects in the context of BRAF mutations.
  • To validate BRAF as a therapeutic target by assessing drug specificity.

Main Methods:

  • Generated drug-resistant oncogenic BRAF variants by mutating the gatekeeper residue.
  • Assessed the sensitivity of BRAF signaling and tumor growth to sorafenib and PLX4720 in the presence of resistant BRAF mutants.
  • Compared the direct versus indirect effects of BRAF inhibitors on tumor cell proliferation and survival.

Main Results:

  • Sorafenib inhibited tumor growth even when BRAF signaling was resistant to it.
  • PLX4720 inhibited both BRAF signaling and tumor growth, indicating direct targeting.
  • These findings clearly distinguish the mechanisms of action for sorafenib and PLX4720.

Conclusions:

  • Sorafenib's antitumor effects are independent of direct BRAF inhibition.
  • PLX4720 directly targets oncogenic BRAF to inhibit tumor growth.
  • This research clarifies drug mechanisms, crucial for optimizing cancer therapies targeting BRAF.

More Related Videos

Bioluminescence Resonance Energy Transfer (BRET)-Based Assay for Measuring Interactions of CRAF with 14-3-3 Proteins in Live Cells06:44

Bioluminescence Resonance Energy Transfer (BRET)-Based Assay for Measuring Interactions of CRAF with 14-3-3 Proteins in Live Cells

Published on: March 1, 2024

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Related Concept Videos

The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...